Clinico-Epidemiological Study of Pancreatic, Gall Bladder and Biliary Tract Cancers at Clinical Oncology Department Tanta University Hospitals

Abdelwahed, Zeinab Mohamed; Darwish, Sara Abdelrahman; Elmashad, Nehal Mohamed; Tawfik, Hesham Ahmed

doi:10.21608/jcbr.2023.220856.1307

Clinico-Epidemiological Study of Pancreatic, Gall Bladder and Biliary Tract Cancers at Clinical Oncology Department Tanta University Hospitals

Document Type : Original Article

Authors

¹ Clinical Oncology &amp;amp; Nuclear Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

² Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

10.21608/jcbr.2023.220856.1307

Abstract

Background: In Egypt, pancreatic cancer (PC) is the 11th most prevalent malignancy and represents 2.2% of all cancers. PCs cause 3.2% of cancer deaths, ranking 8th. Gall bladder cancers account for 0.70% of malignancies in Egypt. Gall bladder cancer accounts for 0.77% of cancer deaths. Gallbladder cancers account for 0.8% of male malignancies in Gharbia and 0.7% in females. This retrospective study aimed to determine the incidence of pancreatic, gall bladder and biliary tract cancers (BTCs), describe the clinico-pathological pattern of pancreatic, gall bladder and BTCs, and detect progression free survival (PFS), disease free survival (DFS) and overall survival (OS) in correlation with prognostic factors.

Methods: This retrospective hospital based clinico-epidemiological study was carried out on 299 patients who were histo-pathological proved pancreatic or biliary tract malignancies through the period from Jan 2015 to Dec 2020 at Clinical Oncology Department Tanta university Hospital.

Results: The estimated median OS for PC patients was 8 months, while the estimated median PFS was 4 months and the estimated median DFS was 7 months. As regard BTC, the estimated median OS was 12 months, the estimated median PFS was 3 and the estimated median DFS was 5 months.

Conclusions: We advocate for the use of genetic counselling after testing to educate families about specific genetic disorders, the risks and advantages of testing, disease management, and potential treatment choices. It is important to promote community-specific cancer prevention initiatives, especially those aimed at reducing cigarette use and treating hepatitis C.

Keywords

Main Subjects